Update in tuberculosis 2009.
Daley
Charles L
CL
University of Colorado, Denver, Colorado 80206, USA. daleyc@njhealth.org
D000081:Acetamides / Q000627:therapeutic use; D000818:Animals; D000995:Antitubercular Agents / Q000627:therapeutic use; D001372:Aza Compounds / Q000627:therapeutic use; D064687:Diarylquinolines; D024841:Fluoroquinolones; D006801:Humans; D000069349:Linezolid; D051379:Mice; D000077266:Moxifloxacin; D023303:Oxazolidinones / Q000627:therapeutic use; D011804:Quinolines / Q000627:therapeutic use; D012293:Rifampin / Q000031:analogs & derivatives / Q000627:therapeutic use; D014376:Tuberculosis / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D032581:Tuberculosis Vaccines / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use; D014815:Vitamins / Q000627:therapeutic use
D000081:Acetamides; D000995:Antitubercular Agents; D001372:Aza Compounds; D064687:Diarylquinolines; D024841:Fluoroquinolones; D023303:Oxazolidinones; D011804:Quinolines; D032581:Tuberculosis Vaccines; D014815:Vitamins; D014807:Vitamin D; C493870:bedaquiline; D000069349:Linezolid; D000077266:Moxifloxacin; D012293:Rifampin; C018421:rifapentine